Key terms
About TLSA
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TLSA news
Yesterday
7:27am ET
Tiziana Expands MS Treatment Access Program
Apr 22
10:57am ET
Tiziana’s MS Drug Shows Promising Patient Outcomes
Apr 22
7:21am ET
Tiziana Life Sciences announces additional clinical improvements in EAP
Apr 19
7:31am ET
Tiziana Life Sciences’ MS Treatment Shows Potential
Apr 19
7:02am ET
Tiziana Life Sciences announces study results on foralumab published
Apr 18
7:27am ET
Tiziana’s Foralumab Shows Promise for MS Treatment
Apr 18
7:10am ET
Tiziana Life Sciences announces new PET imaging data on foralumab
Mar 05
7:01am ET
Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer’s
No recent press releases are available for TLSA
TLSA Financials
Key terms
Ad Feedback
TLSA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TLSA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range